Description
═══════════════════════════════════
THE SCIENCE OF SELECTIVE FAT BREAKDOWN
═══════════════════════════════════
Most compounds that touch fat metabolism also touch everything else — insulin, blood sugar, muscle tissue, cortisol. AOD-9604 was engineered to be different.
Isolated from the C-terminal region of human growth hormone (amino acids 176–191 with an N-terminus tyrosine modification for enhanced stability), AOD-9604 operates on a single, targeted pathway: it binds beta-3 adrenergic receptors in adipose tissue, upregulates hormone-sensitive lipase, and initiates the breakdown of stored triglycerides into free fatty acids — all without activating the hGH/IGF-1 axis that drives broader anabolic effects.
The result? A compound that speaks directly to fat cells while leaving everything else alone.
═══════════════════════════════════
MECHANISM: HOW AOD-9604 WORKS
═══════════════════════════════════
→ LIPOLYSIS ACTIVATION
AOD-9604 stimulates the breakdown of stored body fat (lipolysis) through beta-3 adrenergic receptor signaling — the same pathway that governs fat mobilization during fasting and exercise. Research in obese animal models demonstrated that AOD-9604 restored beta-3 adrenergic receptor RNA expression to levels comparable to lean subjects.
→ LIPOGENESIS INHIBITION
Beyond burning existing fat, AOD-9604 simultaneously inhibits lipogenesis — the formation of new fat deposits. This dual action addresses fat from both directions.
→ INSULIN-NEUTRAL PROFILE
Unlike full-length hGH, AOD-9604 does not affect blood glucose regulation or insulin sensitivity. Clinical safety evaluations across 900+ participants across six randomized, double-blind, placebo-controlled trials confirmed no clinically significant alterations in IGF-1 levels, no glucose intolerance, and a safety profile indistinguishable from placebo.
→ NO ANABOLIC INTERFERENCE
AOD-9604 does not stimulate muscle growth or trigger the widespread hormonal cascade of growth hormone therapy. It isolates fat metabolism — and nothing else.
═══════════════════════════════════
RESEARCH DOSING PROTOCOL
═══════════════════════════════════
RECONSTITUTION
Add 2.0–3.0mL bacteriostatic water to the 5mg lyophilized vial.
Standard 2mL reconstitution yields: 2,500 mcg/mL concentration.
Use U-100 insulin syringes (29–31 gauge, 0.5 inch needle) for precise measurement.
DAILY DOSING RANGE
– Beginner protocol: 300 mcg/day — assess individual response over 4 weeks
– Standard protocol: 400 mcg/day — most common in research and wellness clinic settings
– Advanced protocol: 500 mcg/day — split into 250 mcg AM + 250 mcg early afternoon
TIMING (CRITICAL)
Administer in a fasted state — upon waking, 30–60 minutes before first meal.
Low insulin conditions at the time of administration optimize the lipolytic signaling environment. Consuming food within the fasting window may blunt fat mobilization activity.
INJECTION SITES
Subcutaneous injection into areas with adequate adipose tissue:
– Abdominal region (rotate positions at least 2 inches from navel)
– Outer thigh
– Upper arm
Pinch skin fold, insert needle at 45–90° depending on tissue depth. Inject slowly and steadily. Rotate sites systematically to avoid tissue irritation.
CYCLE LENGTH
– Initial assessment cycle: 8–12 weeks
– Extended research protocols: up to 24 weeks with physician oversight
– Post-cycle break: 4–8 weeks recommended
– One 5mg vial at 300mcg/day yields approximately 16 days of use
– 12-week protocol requires approximately 5–6 vials
═══════════════════════════════════
STORAGE & HANDLING
═══════════════════════════════════
– Lyophilized (dry powder) — stable at room temperature prior to reconstitution
– Post-reconstitution: refrigerate at 2–8°C (36–46°F)
– Protect from light and agitation
– Do not freeze reconstituted solution
– Use within 28 days of reconstitution
═══════════════════════════════════
WHAT MAKES AOD-9604 DIFFERENT
═══════════════════════════════════
The peptide research space is crowded. Here’s what makes AOD-9604 a category of its own:
✦ PRECISION WITHOUT COMPROMISE
GLP-1 agonists reduce appetite. Full hGH alters dozens of metabolic pathways. AOD-9604 has one job — fat metabolism — and it doesn’t interfere with anything else.
✦ A SAFETY RECORD THAT HOLDS UP
Six randomized controlled trials, 900+ subjects, up to 24 weeks of continuous dosing. The safety profile was described by researchers as “indistinguishable from placebo.” No antibody formation. No IGF-1 elevation. No glucose disruption.
✦ DOES NOT SUPPRESS APPETITE
Unlike GLP-1 peptides, AOD-9604 is appetite-neutral. It works purely at the metabolic level — no nausea, no satiety signaling, no GI burden.
✦ FASTED-STATE SYNERGY
Morning administration in a fasted state aligns AOD-9604’s lipolytic activity with the body’s natural fat-mobilization window, creating a compounding effect rather than working against circadian metabolism.
═══════════════════════════════════
VIAL SPECIFICATIONS
═══════════════════════════════════
Peptide: AOD-9604 (HGH Fragment 176-191)
Also known as: Anti-Obesity Drug 9604 | hGH Frag 176-191
Sequence: Tyr-hGH(176-191)
Molecular Weight: 1815.14 g/mol
Form: Lyophilized powder
Amount: 2-10mg per vial
Purity: ≥98% (HPLC verified)
Testing: Third-party tested | Batch COA available
Storage (pre-reconstitution): Room temperature, dry, light-protected
Storage (post-reconstitution): 2–8°C refrigerated
